Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1994 Jul;112(3):963–971. doi: 10.1111/j.1476-5381.1994.tb13175.x

Endothelin-1-induced myocardial ischaemia and oedema in the rat: involvement of the ETA receptor, platelet-activating factor and thromboxane A2.

J G Filep 1, A Fournier 1, E Földes-Filep 1
PMCID: PMC1910206  PMID: 7921626

Abstract

1. The objectives of the present experiments were to assess the role of ETA receptors in mediating endothelin-1 (ET-1)-induced myocardial ischaemia and oedema and to study the involvement of platelet-activating factor (PAF) and thromboxane A2 (TxA2) in these actions of ET-1 in rats. 2. Intravenous bolus injection of ET-1 (0.1-2 nmol kg-1) into anaesthetized rats induced ST segment elevation of the electrocardiogram in a dose-dependent manner without causing arrhythmias. ST segment elevation developed within 20-90 s and persisted for at least 10-20 min following administration of ET-1. 3. Pretreatment of the animals with the selective endothelin ETA receptor antagonist, FR 139317 (2.5 mg kg-1, i.v.) inhibited by 86% the ST segment elevation elicited by ET-1 (1 nmol kg-1). Pretreatment with intravenous administration of BM 13505 (1 mg kg-1), a TxA2 receptor antagonist, OKY-046 (10 mg kg-1), a thromboxane synthase inhibitor or the specific PAF receptor antagonist, WEB 2086 (1 mg kg-1) or BN 52021 (10 mg kg-1) markedly suppressed ST segment elevation in response to ET-1. Infusion of indomethacin (3 mg kg-1 bolus plus 2 mg kg-1 h-1) did not significantly affect ET-1-induced ST segment elevation. 4. Bolus injection of ET-1 (1 nmol kg-1, i.v.) to conscious rats resulted in a prolonged pressor effect preceded by a transient depressor response. Corresponding to changes in blood pressure, a small transient tachycardia was followed by a sustained bradycardia.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arai H., Hori S., Aramori I., Ohkubo H., Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990 Dec 20;348(6303):730–732. doi: 10.1038/348730a0. [DOI] [PubMed] [Google Scholar]
  2. Aramori I., Nirei H., Shoubo M., Sogabe K., Nakamura K., Kojo H., Notsu Y., Ono T., Nakanishi S. Subtype selectivity of a novel endothelin antagonist, FR139317, for the two endothelin receptors in transfected Chinese hamster ovary cells. Mol Pharmacol. 1993 Feb;43(2):127–131. [PubMed] [Google Scholar]
  3. Casals-Stenzel J., Muacevic G., Weber K. H. Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor. J Pharmacol Exp Ther. 1987 Jun;241(3):974–981. [PubMed] [Google Scholar]
  4. Chester A. H., Dashwood M. R., Clarke J. G., Larkin S. W., Davies G. J., Tadjkarimi S., Maseri A., Yacoub M. H. Influence of endothelin on human coronary arteries and localization of its binding sites. Am J Cardiol. 1989 Jun 1;63(18):1395–1398. doi: 10.1016/0002-9149(89)91055-2. [DOI] [PubMed] [Google Scholar]
  5. Cocks T. M., Faulkner N. L., Sudhir K., Angus J. Reactivity of endothelin-1 on human and canine large veins compared with large arteries in vitro. Eur J Pharmacol. 1989 Nov 14;171(1):17–24. doi: 10.1016/0014-2999(89)90425-1. [DOI] [PubMed] [Google Scholar]
  6. Cox R. H., Bagshaw R. J. Effects of anesthesia on carotid sinus reflex control of arterial hemodynamics in the dog. Am J Physiol. 1980 Nov;239(5):H681–H691. doi: 10.1152/ajpheart.1980.239.5.H681. [DOI] [PubMed] [Google Scholar]
  7. Cristol J. P., Warner T. D., Thiemermann C., Vane J. R. Mediation via different receptors of the vasoconstrictor effects of endothelins and sarafotoxins in the systemic circulation and renal vasculature of the anaesthetized rat. Br J Pharmacol. 1993 Mar;108(3):776–779. doi: 10.1111/j.1476-5381.1993.tb12877.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. D'Orléans-Juste P., Télémaque S., Claing A., Ihara M., Yano M. Human big-endothelin-1 and endothelin-1 release prostacyclin via the activation of ET1 receptors in the rat perfused lung. Br J Pharmacol. 1992 Apr;105(4):773–775. doi: 10.1111/j.1476-5381.1992.tb09055.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dahlén S. E., Björk J., Hedqvist P., Arfors K. E., Hammarström S., Lindgren J. A., Samuelsson B. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci U S A. 1981 Jun;78(6):3887–3891. doi: 10.1073/pnas.78.6.3887. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Douglas S. A., Hiley C. R. Endothelium-dependent mesenteric vasorelaxant effects and systemic actions of endothelin (16-21) and other endothelin-related peptides in the rat. Br J Pharmacol. 1991 Oct;104(2):311–320. doi: 10.1111/j.1476-5381.1991.tb12428.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Eglezos A., Cucchi P., Patacchini R., Quartara L., Maggi C. A., Mizrahi J. Differential effects of BQ-123 against endothelin-1 and endothelin-3 on the rat vas deferens: evidence for an atypical endothelin receptor. Br J Pharmacol. 1993 Jul;109(3):736–738. doi: 10.1111/j.1476-5381.1993.tb13635.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Emori T., Hirata Y., Marumo F. Specific receptors for endothelin-3 in cultured bovine endothelial cells and its cellular mechanism of action. FEBS Lett. 1990 Apr 24;263(2):261–264. doi: 10.1016/0014-5793(90)81388-5. [DOI] [PubMed] [Google Scholar]
  13. Entman M. L., Michael L., Rossen R. D., Dreyer W. J., Anderson D. C., Taylor A. A., Smith C. W. Inflammation in the course of early myocardial ischemia. FASEB J. 1991 Aug;5(11):2529–2537. doi: 10.1096/fasebj.5.11.1868978. [DOI] [PubMed] [Google Scholar]
  14. Ezra D., Goldstein R. E., Czaja J. F., Feuerstein G. Z. Lethal ischemia due to intracoronary endothelin in pigs. Am J Physiol. 1989 Jul;257(1 Pt 2):H339–H343. doi: 10.1152/ajpheart.1989.257.1.H339. [DOI] [PubMed] [Google Scholar]
  15. Feuerstein G., Boyd L. M., Ezra D., Goldstein R. E. Effect of platelet-activating factor on coronary circulation of the domestic pig. Am J Physiol. 1984 Mar;246(3 Pt 2):H466–H471. doi: 10.1152/ajpheart.1984.246.3.H466. [DOI] [PubMed] [Google Scholar]
  16. Filep J. G., Battistini B., Côté Y. P., Beaudoin A. R., Sirois P. Endothelin-1 induces prostacyclin release from bovine aortic endothelial cells. Biochem Biophys Res Commun. 1991 May 31;177(1):171–176. doi: 10.1016/0006-291x(91)91964-e. [DOI] [PubMed] [Google Scholar]
  17. Filep J. G., Földes-Filep E., Rousseau A., Fournier A., Sirois P., Yano M. Endothelin-1 enhances vascular permeability in the rat heart through the ETA receptor. Eur J Pharmacol. 1992 Aug 25;219(2):343–344. doi: 10.1016/0014-2999(92)90318-x. [DOI] [PubMed] [Google Scholar]
  18. Filep J. G., Földes-Filep E., Rousseau A., Sirois P., Fournier A. Vascular responses to endothelin-1 following inhibition of nitric oxide synthesis in the conscious rat. Br J Pharmacol. 1993 Nov;110(3):1213–1221. doi: 10.1111/j.1476-5381.1993.tb13944.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Filep J. G., Sirois M. G., Földes-Filep E., Rousseau A., Plante G. E., Fournier A., Yano M., Sirois P. Enhancement by endothelin-1 of microvascular permeability via the activation of ETA receptors. Br J Pharmacol. 1993 Jul;109(3):880–886. doi: 10.1111/j.1476-5381.1993.tb13657.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Filep J. G., Sirois M. G., Rousseau A., Fournier A., Sirois P. Effects of endothelin-1 on vascular permeability in the conscious rat: interactions with platelet-activating factor. Br J Pharmacol. 1991 Dec;104(4):797–804. doi: 10.1111/j.1476-5381.1991.tb12509.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Filep J., Földes-Filep E., Frölich J. C. Vascular responses to leukotriene B4, C4 and D4 following FPL 55712, indomethacin, saralasin, phentolamine and verapamil in the conscious rat. Br J Pharmacol. 1987 Feb;90(2):431–439. doi: 10.1111/j.1476-5381.1987.tb08973.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Franco-Cereceda A. Endothelin- and neuropeptide Y-induced vasoconstriction of human epicardial coronary arteries in vitro. Br J Pharmacol. 1989 Jul;97(3):968–972. doi: 10.1111/j.1476-5381.1989.tb12038.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Földes-Filep E., Braquet P., Filep J. Inhibition by BN 52021 (ginkgolide B) of the binding of [3H]-platelet-activating factor to human neutrophil granulocytes. Biochem Biophys Res Commun. 1987 Nov 13;148(3):1412–1417. doi: 10.1016/s0006-291x(87)80289-9. [DOI] [PubMed] [Google Scholar]
  24. Garcia-Szabo R., Kern D. F., Malik A. B. Pulmonary vascular response to thrombin: effects of thromboxane synthetase inhibition with OKY-046 and OKY-1581. Prostaglandins. 1984 Dec;28(6):851–866. doi: 10.1016/0090-6980(84)90039-x. [DOI] [PubMed] [Google Scholar]
  25. Gardiner S. M., Compton A. M., Bennett T. Regional hemodynamic effects of endothelin-1 in conscious, unrestrained, Wistar rats. J Cardiovasc Pharmacol. 1989;13 (Suppl 5):S202–S204. doi: 10.1097/00005344-198900135-00057. [DOI] [PubMed] [Google Scholar]
  26. Grega G. J., Adamski S. W., Dobbins D. E. Physiological and pharmacological evidence for the regulation of permeability. Fed Proc. 1986 Feb;45(2):96–100. [PubMed] [Google Scholar]
  27. Harada K., Miwa A., Kaneta S., Izawa T., Fukushima H., Ogawa N. Effects of KRN2391, nicorandil and diltiazem on the changes in the electrocardiogram caused by endothelin-1 in anaesthetized rats. Br J Pharmacol. 1993 Jul;109(3):679–684. doi: 10.1111/j.1476-5381.1993.tb13627.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Harrison V. J., Randriantsoa A., Schoeffter P. Heterogeneity of endothelin-sarafotoxin receptors mediating contraction of pig coronary artery. Br J Pharmacol. 1992 Mar;105(3):511–513. doi: 10.1111/j.1476-5381.1992.tb09009.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Hermán F., Magyar K., Chabrier P. E., Braquet P., Filep J. Prostacyclin mediates antiaggregatory and hypotensive actions of endothelin in anaesthetized beagle dogs. Br J Pharmacol. 1989 Sep;98(1):38–40. doi: 10.1111/j.1476-5381.1989.tb16859.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Hermán F., Yano M., Filep J. G. The in vivo antiaggregatory action of endothelin-1 is not mediated through the endothelin ETA receptor. Eur J Pharmacol. 1993 May 12;236(1):143–146. doi: 10.1016/0014-2999(93)90237-c. [DOI] [PubMed] [Google Scholar]
  31. Hirsh P. D., Hillis L. D., Campbell W. B., Firth B. G., Willerson J. T. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med. 1981 Mar 19;304(12):685–691. doi: 10.1056/NEJM198103193041201. [DOI] [PubMed] [Google Scholar]
  32. Hom G. J., Touhey B., Rubanyi G. M. Effects of intracoronary administration of endothelin in anesthetized dogs: comparison with Bay k 8644 and U 46619. J Cardiovasc Pharmacol. 1992 Feb;19(2):194–200. doi: 10.1097/00005344-199202000-00007. [DOI] [PubMed] [Google Scholar]
  33. Hwang S. B. Identification of a second putative receptor of platelet-activating factor from human polymorphonuclear leukocytes. J Biol Chem. 1988 Mar 5;263(7):3225–3233. [PubMed] [Google Scholar]
  34. Ihara M., Noguchi K., Saeki T., Fukuroda T., Tsuchida S., Kimura S., Fukami T., Ishikawa K., Nishikibe M., Yano M. Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci. 1992;50(4):247–255. doi: 10.1016/0024-3205(92)90331-i. [DOI] [PubMed] [Google Scholar]
  35. Kasuya Y., Takuwa Y., Yanagisawa M., Kimura S., Goto K., Masaki T. Endothelin-1 induces vasoconstriction through two functionally distinct pathways in porcine coronary artery: contribution of phosphoinositide turnover. Biochem Biophys Res Commun. 1989 Jun 30;161(3):1049–1055. doi: 10.1016/0006-291x(89)91349-1. [DOI] [PubMed] [Google Scholar]
  36. Kurihara H., Yamaoki K., Nagai R., Yoshizumi M., Takaku F., Satoh H., Inui J., Yazaki Y. Endothelin: a potent vasoconstrictor associated with coronary vasospasm. Life Sci. 1989;44(25):1937–1943. doi: 10.1016/0024-3205(89)90406-2. [DOI] [PubMed] [Google Scholar]
  37. Le Monnier de Gouville A. C., Mondot S., Lippton H., Hyman A., Cavero I. Hemodynamic and pharmacological evaluation of the vasodilator and vasoconstrictor effects of endothelin-1 in rats. J Pharmacol Exp Ther. 1990 Jan;252(1):300–311. [PubMed] [Google Scholar]
  38. Lin H. Y., Kaji E. H., Winkel G. K., Ives H. E., Lodish H. F. Cloning and functional expression of a vascular smooth muscle endothelin 1 receptor. Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3185–3189. doi: 10.1073/pnas.88.8.3185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. López-Farré A., Gómez-Garre D., Bernabeu F., Montañs I., Millás I., López-Novoa J. M. Renal effects and mesangial cell contraction induced by endothelin are mediated by PAF. Kidney Int. 1991 Apr;39(4):624–630. doi: 10.1038/ki.1991.74. [DOI] [PubMed] [Google Scholar]
  40. Matsuyama K., Yasue H., Okumura K., Saito Y., Nakao K., Shirakami G., Imura H. Increased plasma level of endothelin-1-like immunoreactivity during coronary spasm in patients with coronary spastic angina. Am J Cardiol. 1991 Oct 15;68(10):991–995. doi: 10.1016/0002-9149(91)90484-3. [DOI] [PubMed] [Google Scholar]
  41. McMurdo L., Corder R., Thiemermann C., Vane J. R. Incomplete inhibition of the pressor effects of endothelin-1 and related peptides in the anaesthetized rat with BQ-123 provides evidence for more than one vasoconstrictor receptor. Br J Pharmacol. 1993 Feb;108(2):557–561. doi: 10.1111/j.1476-5381.1993.tb12840.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Molenaar P., O'Reilly G., Sharkey A., Kuc R. E., Harding D. P., Plumpton C., Gresham G. A., Davenport A. P. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res. 1993 Mar;72(3):526–538. doi: 10.1161/01.res.72.3.526. [DOI] [PubMed] [Google Scholar]
  43. Nichols A. J., Koster P. F., Ohlstein E. H. The effect of diltiazem on the coronary haemodynamic and cardiac functional effects produced by intracoronary administration of endothelin-1 in the anaesthetized dog. Br J Pharmacol. 1990 Mar;99(3):597–601. doi: 10.1111/j.1476-5381.1990.tb12975.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Pang D. C., Johns A., Patterson K., Botelho L. H., Rubanyi G. M. Endothelin-1 stimulates phosphatidylinositol hydrolysis and calcium uptake in isolated canine coronary arteries. J Cardiovasc Pharmacol. 1989;13 (Suppl 5):S75–S84. doi: 10.1097/00005344-198900135-00018. [DOI] [PubMed] [Google Scholar]
  45. Piper P. J. Formation and actions of leukotrienes. Physiol Rev. 1984 Apr;64(2):744–761. doi: 10.1152/physrev.1984.64.2.744. [DOI] [PubMed] [Google Scholar]
  46. Ray S. G., McMurray J. J., Morton J. J., Dargie H. J. Circulating endothelin in acute ischaemic syndromes. Br Heart J. 1992 May;67(5):383–386. doi: 10.1136/hrt.67.5.383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Rogerson M. E., Cairns H. S., Fairbanks L. D., Westwick J., Neild G. H. Endothelin-1 in the rabbit: interactions with cyclo-oxygenase and NO-synthase products. Br J Pharmacol. 1993 Mar;108(3):838–843. doi: 10.1111/j.1476-5381.1993.tb12887.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Saeki T., Ihara M., Fukuroda T., Yamagiwa M., Yano M. [Ala1,3,11,15]endothelin-1 analogs with ETB agonistic activity. Biochem Biophys Res Commun. 1991 Aug 30;179(1):286–292. doi: 10.1016/0006-291x(91)91367-l. [DOI] [PubMed] [Google Scholar]
  49. Sakurai T., Yanagisawa M., Takuwa Y., Miyazaki H., Kimura S., Goto K., Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 1990 Dec 20;348(6303):732–735. doi: 10.1038/348732a0. [DOI] [PubMed] [Google Scholar]
  50. Samson W. K., Skala K. D., Alexander B. D., Huang F. L. Pituitary site of action of endothelin: selective inhibition of prolactin release in vitro. Biochem Biophys Res Commun. 1990 Jun 15;169(2):737–743. doi: 10.1016/0006-291x(90)90393-2. [DOI] [PubMed] [Google Scholar]
  51. Simonson M. S., Dunn M. J. The molecular mechanisms of cardiovascular and renal regulation by endothelin peptides. J Lab Clin Med. 1992 Jun;119(6):622–639. [PubMed] [Google Scholar]
  52. Sogabe K., Nirei H., Shoubo M., Nomoto A., Ao S., Notsu Y., Ono T. Pharmacological profile of FR139317, a novel, potent endothelin ETA receptor antagonist. J Pharmacol Exp Ther. 1993 Mar;264(3):1040–1046. [PubMed] [Google Scholar]
  53. Sokolovsky M. Endothelins and sarafotoxins: physiological regulation, receptor subtypes and transmembrane signaling. Pharmacol Ther. 1992;54(2):129–149. doi: 10.1016/0163-7258(92)90030-4. [DOI] [PubMed] [Google Scholar]
  54. Takayasu M., Kondo K., Terao S. Endothelin-induced mobilization of Ca2+ and the possible involvement of platelet activating factor and thromboxane A2. Biochem Biophys Res Commun. 1989 Apr 28;160(2):751–757. doi: 10.1016/0006-291x(89)92497-2. [DOI] [PubMed] [Google Scholar]
  55. Terashita Z., Shibouta Y., Imura Y., Iwasaki K., Nishikawa K. Endothelin-induced sudden death and the possible involvement of platelet activating factor (PAF). Life Sci. 1989;45(20):1911–1918. doi: 10.1016/0024-3205(89)90545-6. [DOI] [PubMed] [Google Scholar]
  56. Thiemermann C., May G. R., Page C. P., Vane J. R. Endothelin-1 inhibits platelet aggregation in vivo: a study with 111indium-labelled platelets. Br J Pharmacol. 1990 Feb;99(2):303–308. doi: 10.1111/j.1476-5381.1990.tb14699.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Toyo-oka T., Aizawa T., Suzuki N., Hirata Y., Miyauchi T., Shin W. S., Yanagisawa M., Masaki T., Sugimoto T. Increased plasma level of endothelin-1 and coronary spasm induction in patients with vasospastic angina pectoris. Circulation. 1991 Feb;83(2):476–483. doi: 10.1161/01.cir.83.2.476. [DOI] [PubMed] [Google Scholar]
  58. Tsuji S., Sawamura A., Watanabe H., Takihara K., Park S. E., Azuma J. Plasma endothelin levels during myocardial ischemia and reperfusion. Life Sci. 1991;48(18):1745–1749. doi: 10.1016/0024-3205(91)90211-s. [DOI] [PubMed] [Google Scholar]
  59. Watanabe T., Suzuki N., Shimamoto N., Fujino M., Imada A. Contribution of endogenous endothelin to the extension of myocardial infarct size in rats. Circ Res. 1991 Aug;69(2):370–377. doi: 10.1161/01.res.69.2.370. [DOI] [PubMed] [Google Scholar]
  60. Whittle B. J., Payne A. N., Esplugues J. V. Cardiopulmonary and gastric ulcerogenic actions of endothelin-1 in the guinea pig and rat. J Cardiovasc Pharmacol. 1989;13 (Suppl 5):S103–S123. doi: 10.1097/00005344-198900135-00026. [DOI] [PubMed] [Google Scholar]
  61. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988 Mar 31;332(6163):411–415. doi: 10.1038/332411a0. [DOI] [PubMed] [Google Scholar]
  62. Yasuda M., Kohno M., Tahara A., Itagane H., Toda I., Akioka K., Teragaki M., Oku H., Takeuchi K., Takeda T. Circulating immunoreactive endothelin in ischemic heart disease. Am Heart J. 1990 Apr;119(4):801–806. doi: 10.1016/s0002-8703(05)80315-1. [DOI] [PubMed] [Google Scholar]
  63. de Nucci G., Thomas R., D'Orleans-Juste P., Antunes E., Walder C., Warner T. D., Vane J. R. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A. 1988 Dec;85(24):9797–9800. doi: 10.1073/pnas.85.24.9797. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES